Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Interested in receiving a copy of the Contemporary Pediatrics journal every month?
Want to stay up to date with pediatric news? Subscribe to the Contemporary Pediatrics e-newsletter to receive emailed updates regarding new data, pediatric clinical trials, puzzler cases, FDA news, and much more.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, December 16, to Friday, December 20, 2024), and click on each link to read and watch anything you may have missed.
Organon's tapinarof cream, 1% (VTAMA), an aryl hydrocarbon receptor agonist, once-daily, steroid-free topical cream, has been approved by the FDA to treat atopic dermatitis in patients aged 2 years and up, according to a press release from Organon.1,2
"It's rare to first of all, have a steroid free option, but also to have something that's going to work in a completely different mechanism," John Browning, MD, FAAD, FAAP, in the above interview with Contemporary Pediatrics.
Browning is a board-certified pediatric and adult dermatologist in San Antonio, Texas, and is an assistant professor at the Baylor College of Medicine, as well as the chief of Dermatology at the Children's Hospital of San Antonio.
"Instead of just blocking inflammation, with tapinarof we're actually seeing the epidermal barrier, so your skin integrity improves with it," said Browning. "The other thing that's unique is the ability to go through these disease free intervals, [basically] a time when the skin clears up. It's very exciting to have a steroid free option for treating atopic dermatitis aged 2 and up."
For additional commentary on the FDA approval of tapinarof cream, 1%, Lawrence Eichenfield, MD, professor of dermatology and pediatrics at the University of California, San Diego, joined us in a video interview discussion.
“This is the first approval for tapinarof for atopic dermatitis,” he stated. “We get [approval] from age 2 [years] upward through adults at the same time with the same formulation that we’ve had experience with in psoriasis."
"“I think it’s exciting to get newer non-steroidals in our hands,” said Eichenfield. “We certainly have patients who are very concerned about topical corticosteroids, and also many patients where we can’t necessarily treat with just topical corticosteroids long term. So tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages.”
Nemolizumab (Nemluvio; Galderma) has been approved by the FDA to treat patients aged 12 years and up with moderate-to-severe atopic dermatitis in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI), when disease is not adequately controlled with topical prescription therapies, according to a press release from Galderma.
With the approval, nemolizumab becomes the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, Galderma stated in a press release announcing the federal agency's decision. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis.
From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.
the FDA has granted approval to Mesoblast's remestemcel-L-rknd (Ryoncil) for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged 2 months and older, according to a press release from the federal agency.
With the approval of the allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L-rknd is the first FDA-approved MSC therapy.
